Perforation

Electrosurgery Market to be Worth $8.99 Billion by 2031 - Exclusive Report by Meticulous Research®

Retrieved on: 
Mittwoch, Mai 8, 2024
Smoke, United Nations, Risk, General surgery, Surgeon, Electrosurgery, Medtronic, Smith, Olympus Corporation, Boston Scientific, Lip, Perforation, Prevalence, Skin, Medical tourism, Spine, Obstetrics, Ageing, Argon, Plasma, Conditional sentence, Hospital, Generator, Geography, ENT, Johnson & Johnson, Bleeding, Incidence, Government, BPH, Stryker Corporation, Steris, ASC, Disease, United, Patient, Coagulation, Circulatory system, Cancer, Growth, Dentistry

Additionally, factors such as rising healthcare expenditure and market expansion in emerging economies are expected to create market growth opportunities.

Key Points: 
  • Additionally, factors such as rising healthcare expenditure and market expansion in emerging economies are expected to create market growth opportunities.
  • However, the risks associated with electrosurgical procedures and the shortage of surgeons restrain the growth of this market.
  • The report also includes an extensive assessment of the key growth strategies adopted by leading market players over the past three years.
  • The global electrosurgery market has witnessed several product launches, product approvals, acquisitions, and expansions in the last couple of years.

Electrosurgery Market to be Worth $8.99 Billion by 2031 - Exclusive Report by Meticulous Research®

Retrieved on: 
Mittwoch, Mai 8, 2024
Smoke, United Nations, Risk, General surgery, Surgeon, Electrosurgery, Medtronic, Smith, Olympus Corporation, Boston Scientific, Lip, Perforation, Prevalence, Skin, Medical tourism, Spine, Obstetrics, Ageing, Argon, Plasma, Conditional sentence, Hospital, Generator, Geography, ENT, Johnson & Johnson, Bleeding, Incidence, Government, BPH, Stryker Corporation, Steris, ASC, Disease, United, Patient, Coagulation, Circulatory system, Cancer, Growth, Dentistry

Additionally, factors such as rising healthcare expenditure and market expansion in emerging economies are expected to create market growth opportunities.

Key Points: 
  • Additionally, factors such as rising healthcare expenditure and market expansion in emerging economies are expected to create market growth opportunities.
  • However, the risks associated with electrosurgical procedures and the shortage of surgeons restrain the growth of this market.
  • The report also includes an extensive assessment of the key growth strategies adopted by leading market players over the past three years.
  • The global electrosurgery market has witnessed several product launches, product approvals, acquisitions, and expansions in the last couple of years.

Rx Green Technologies Launches New Ready to Use Coco Grow Bags

Retrieved on: 
Mittwoch, April 10, 2024
Nutrient, COGS, Drainage, Plant, Breathability, Water, Perforation, Coco, RTU, Tea

DENVER, April 10, 2024 /PRNewswire/ -- RX Green Technologies ("RX Green"), a leading developer and manufacturer of cannabis cultivation nutrients, growing media, and services, today announces the launch of the newest product in its portfolio: Ready to Use (RTU) Coco Grow Bags. Available in both one- and two-gallon sizes, RTU bags deliver Rx Green's premium, buffered coco in bags specifically designed to support healthy cannabis plant growth from clone to harvest, while also reducing time, labor and resources – ultimately lowering COGs and helping to drive operational efficiency.

Key Points: 
  • Available in both one- and two-gallon sizes, Rx Green's grow bags deliver premium buffered coco in an easy-to-use, efficient design so cultivators can simply Rip.
  • DENVER, April 10, 2024 /PRNewswire/ -- RX Green Technologies ("RX Green"), a leading developer and manufacturer of cannabis cultivation nutrients, growing media, and services, today announces the launch of the newest product in its portfolio: Ready to Use (RTU) Coco Grow Bags .
  • Like all of Rx Green's coco coir products, RTU bags come filled with OMRI-listed clean, buffered coco coir sourced only from RHP-certified sources.
  • "Our RTU bags address that challenge  - delivering premium quality coco in an affordable, easy to use solution."

HealthpointCapital Acquires SteriCUBE®, the Leading Multi-Tray, Safer Sterilization Platform

Retrieved on: 
Mittwoch, April 10, 2024
FDA, MTS, ProCare, Hospital, The Company, Perforation, Partner (business rank), Patent, Acquisition, Communication, Marketing, SAN, Sterilization

The SteriCUBE® Multiple Tray Sterilization (MTS) System is a patented, environmentally friendly technology for simultaneous sterilization of instrument-holding trays.

Key Points: 
  • The SteriCUBE® Multiple Tray Sterilization (MTS) System is a patented, environmentally friendly technology for simultaneous sterilization of instrument-holding trays.
  • Simultaneous with the closing of the transaction, HealthpointCapital is bringing in a new leadership team into SteriCUBE.
  • Chris added: "Every day, the sterilization and processing departments of hospitals handle some of the healthcare system's most critical tasks.
  • Schulte, Roth & Zabel LLP and Knobbe Martens Olson & Bear LLP provided legal counsel to HealthpointCapital.

2025 Toyota 4Runner Refines Adventure Ready Heritage

Retrieved on: 
Mittwoch, April 10, 2024
Land cruiser, ARB, Radar, Nickel–metal hydride battery, Signature, Corrosion, Tundra, Old, Qi, AC, Control, Perforation, Beyond Zero, Blind spot monitor, OME, MID, Android, Torque, 4Runner, Traction, TRD, PDA, HAC, TNGA-F, Lane departure warning system, SAN, Safety, Mirai, RIGID, Carbon, DNA, BSM, Multimedia, TSS, Sequoia, Sale, Adaptive cruise control, BEV, SR5, Smart key, MAX, Roadside assistance, Road

The all-new 2025 Toyota 4Runner stays true to its original concept, as an extremely capable, dynamic, and durable off-roader and will continue to provide owners a window to bigger worlds.

Key Points: 
  • The all-new 2025 Toyota 4Runner stays true to its original concept, as an extremely capable, dynamic, and durable off-roader and will continue to provide owners a window to bigger worlds.
  • The 2025 4Runner will be built in Toyota Motor Corporation's Tahara plant in Japan and will arrive in the U.S. in the fall of 2024.
  • The 2025 4Runner introduces its first-ever Platinum grade which offers customers a high-end, luxury experience with all the capability you expect in a 4Runner.
  • All 2025 4Runner models come standard with Toyota Safety Sense 3.0, Toyota's suite of active safety and convenience systems.

Olympus Announces FDA Clearance of RenaFlex™, Its First Single-use Flexible Ureteroscope

Retrieved on: 
Dienstag, April 2, 2024
System, U.S. FDA, Burns, Urology, Small Business Saturday, Lithotripsy, Endoscopy, Risk, Patient, Perforation, Infection, Health professional, Bleeding, Ureteroscopy, Kidney, Ureter, Urethra, Physician, Medical imaging

CENTER VALLEY, Pa., April 2, 2024 /PRNewswire/ -- Olympus, a global medical technology company committed to making people's lives healthier, safer and more fulfilling, announced today U.S. FDA 510(k) clearance of its first single-use ureteroscope system, RenaFlex™, with full market availability to be announced at a later date.

Key Points: 
  • The RenaFlex single-use flexible ureteroscope system is used to access and visualize the urinary tract to diagnose and treat urinary diseases and disorders, such as kidney stones.
  • The RenaFlex ureteroscope can be used with endotherapeutic accessories to perform diagnostic and therapeutic procedures within the urinary tract.
  • The RenaFlex Single-use Ureteroscope works in combination with the compatible CV-S1 Video System Center for flexible Single-use Endoscopes.
  • Visit the urology product page for more information about the complete line of Olympus urology solutions.

Olympus Partners with American Lung Association on Patient Education for Lung Cancer Screening

Retrieved on: 
Mittwoch, März 27, 2024
Diagnosis, Biopsy, Lung cancer, Medicine, Immunotherapy, Disease, Infection, Partnership, Patient, Sore throat, Perforation, Cancer, United, Olympus Corporation, Senior, Lymph, Bleeding, EUS, American Lung Association, Physician, Medical imaging

CENTER VALLEY, Pa., March 27, 2024 /PRNewswire/ -- Olympus Corporation of the Americas, a global medical technology company committed to making people's lives healthier, safer and more fulfilling, is now partnering with the American Lung Association to educate lung cancer patients about the care pathway for diagnosing and staging lung nodules.

Key Points: 
  • The lung nodules educational resources , sponsored by Olympus, help patients understand the diagnosis and staging process for lung nodules and why it is important to their treatment journey.
  • "Olympus is very excited to support this great new educational resource for lung cancer patients through our partnership with the American Lung Association," said Jovan Reyerson, Senior Vice President of Medical and Scientific Affairs at Olympus Corporation of the Americas.
  • Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), a procedure pioneered by Olympus, has helped lay the groundwork for targeted cancer treatment such as immunotherapy.
  • Lung cancer remains the leading cause of cancer death in the United States.² Early detection of lung cancer is key as the 5-year relative survival rate for non-small cell lung cancer is about 65% when caught at a localized stage.

Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS®

Retrieved on: 
Dienstag, März 26, 2024
Ulcer, Myocardial infarction, Liver disease, Endo International, Hyperkalemia, Horizon Therapeutics, Patient, Stroke, History, Aspirin, CABG, Pain, Famotidine, Itch, NSAID, Stomach, Central nervous system, Edema, ACE, Risk, CNS, Perforation, Peptic ulcer disease, Heart failure, Anaphylaxis, Amgen, Fatigue, Hypertension, Delirium, Kidney, Coma, Tablet, Eosinophilia, Nonsteroidal anti-inflammatory drug, Senior, Rash, Lethargy, OTC, Creatinine, Hepatotoxicity, Ibuprofen, Hypersensitivity, Esophagus, Jaundice, Rheumatoid arthritis, Water retention, Seizure, Incidence, Gastrointestinal bleeding, Inflammation, Extrapyramidal system, Ischemia, Diarrhea, GI, Nausea, Diuretic, Bleeding, NSAIDS, Physician, Osteoarthritis, Pharmaceutical industry

DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.

Key Points: 
  • DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.
  • Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at a greater risk for serious GI events.
  • Ibuprofen and famotidine tablets should not be administered to patients with a history of hypersensitivity to other H2-receptor antagonists.
  • If ibuprofen and famotidine is used in patients with a recent MI, monitor patients for signs of cardiac ischemia.

Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS®

Retrieved on: 
Dienstag, März 26, 2024
Ulcer, Myocardial infarction, Liver disease, Endo International, Hyperkalemia, Horizon Therapeutics, Patient, Stroke, History, Aspirin, CABG, Pain, Famotidine, Itch, NSAID, Stomach, Central nervous system, Edema, ACE, Risk, CNS, Perforation, Peptic ulcer disease, Heart failure, Anaphylaxis, Amgen, Fatigue, Hypertension, Delirium, Kidney, Coma, Tablet, Eosinophilia, Nonsteroidal anti-inflammatory drug, Senior, Rash, Lethargy, OTC, Creatinine, Hepatotoxicity, Ibuprofen, Hypersensitivity, Esophagus, Jaundice, Rheumatoid arthritis, Water retention, Seizure, Incidence, Gastrointestinal bleeding, Inflammation, Extrapyramidal system, Ischemia, Diarrhea, GI, Nausea, Diuretic, Bleeding, NSAIDS, Physician, Osteoarthritis, Pharmaceutical industry

DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.

Key Points: 
  • DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.
  • Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at a greater risk for serious GI events.
  • Ibuprofen and famotidine tablets should not be administered to patients with a history of hypersensitivity to other H2-receptor antagonists.
  • If ibuprofen and famotidine is used in patients with a recent MI, monitor patients for signs of cardiac ischemia.

The Makers of HORMEL® Chili Solve the Double-Dip Dilemma with Double Dippable Chips

Retrieved on: 
Dienstag, März 12, 2024
Food, Social media, Perforation, Cheese

AUSTIN, Minn., March 12, 2024 /PRNewswire/ -- The makers of HORMEL® Chili today launched Double Dippable Chips, the first "breakable" chips designed to allow people to double-dip into their favorite chili dips without committing a social faux pas.

Key Points: 
  • AUSTIN, Minn., March 12, 2024 /PRNewswire/ -- The makers of HORMEL® Chili today launched Double Dippable Chips, the first "breakable" chips designed to allow people to double-dip into their favorite chili dips without committing a social faux pas.
  • After rapid prototyping and some serious break-and-dip testing, Double Dippable Chips are now ready to meet some lucky winners.
  • The party-friendly kits include a bag of Double Dippable Chips, a can of HORMEL® Chili and a recipe for a delicious 7-Layer Chili Cheese Dip.
  • HORMEL® Chili Double Dip Kits will ship to winners just in time to enjoy during the upcoming college hoops tournament.